Literatur
- 1
European Association for the Study of the Liver. EASL Clinical Practice Guidelines:
management of cholestatic liver diseases.
J Hepatol.
2009;
51
237-267
- 2
Chapman R, Fevery J, Kalloo A et al.
Diagnosis and management of primary sclerosing cholangitis.
Hepatology.
2010;
51
660-678
- 3
Lindkvist B, Benito Valle de M, Gullberg B et al.
Incidence and prevalence of primary sclerosing cholangitis in a defined adult population
in Sweden.
Hepatology.
2010;
52
571-577
- 4
Tischendorf J J, Hecker H, Kruger M et al.
Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis:
A single center study.
Am J Gastroenterol.
2007;
102
107-114
- 5
Karlsen T H, Schrumpf E, Boberg K M.
Update on primary sclerosing cholangitis.
Dig Liver Dis.
2010;
42
390-400
- 6
Karlsen T H, Franke A, Melum E et al.
Genome-wide association analysis in primary sclerosing cholangitis.
Gastroenterology.
2010;
138
1102-1111
- 7
Hov J R, Keitel V, Laerdahl J K et al.
Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis.
PLoS One.
2010;
5
e12403
- 8
Lindor K D, Kowdley K V, Luketic V A et al.
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Hepatology.
2009;
50
808-814
- 9
Gotthardt D N, Rudolph G, Kloters-Plachky P et al.
Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome
after long-term treatment.
Gastrointest Endosc.
2010;
71
527-534
PD Dr. Christoph Schramm
I. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg
eMail: cschramm@uke.de
